426 / 1345
• Elective dose including draining lymphatic system
• Boost to regional pathologic nodes
• Boost to primary tumor if brachytherapy is not feasible
• Dose needed for tumor control too high for surrounding OAR
• Reduction according to ALARA, as low as reasonably
achievable
• Dose constraints and DVH parameters help to balance
between tumor dose and OAR dose
EBRT for GYN Cancer treatment